Date: 2015-01-21
Type of information: Private placement
Company: Alnylam Pharmaceuticals (USA - MA)
Investors:
Amount: $496.4 million
Funding type: private placement
Planned used: Alnylam Pharmaceuticals intends to use the net proceeds from this offering for general corporate purposes, focused on achieving its Alnylam 2020 profile with 3 marketed products, 10 RNAi therapeutic clinical programs, including 4 in late stages of development, across its 3 Strategic Therapeutic Areas, or "STArs" - Genetic Medicines, Cardio-Metabolic Disease, and Hepatic Infectious Disease - by the end of 2020. Alnylam expects these purposes to include research and development expenses, including clinical trial costs, and other potential expenses as detailed in the prospectus supplement.
Others: Alnylam's form 10-K for tje for the Period Ending 12/31/15 announced that, in January 2015, the company sold an aggregate of 5,447,368 shares of its common stock through an underwritten public offering at a price to the public of $95.00 per * On January 21, 2015, Alnylam Pharmaceuticals, a leading RNAi therapeutics company, announced the pricing of an underwritten registered public offering of 4,736,842 shares of its common stock at a public offering price of $95 per share. All of the shares in the offering are to be sold by Alnylam. The offering is expected to close on or about January 26, 2015 , subject to the satisfaction of customary closing conditions. J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers for the offering. Barclays Capital Inc. , Piper Jaffray & Co. , Cowen and Company, LLC , JMP Securities LLC , and Needham & Company, LLC are acting as co-managers for the offering. Alnylam has granted the underwriters a 30 day option to purchase up to 710,526 additional shares.
share. As a result of the offering, which included the full exercise of the underwriters’ option to purchase additional shares, Alnylam received aggregate net proceeds of $496.4 million, after deducting underwriting discounts and commissions and other offering expenses of $21.1 million.
Therapeutic area:
